Search
  • SBIJI Innovation

Adicet Bio Receives $10 Million Product Development Milestone From Regeneron

August 5, 2020


Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron. ADI-002 is the first of Adicet Bio’s allogeneic off-the-shelf γδ T cell product candidates to specifically target solid tumors. ADI-002 is being developed and engineered by Adicet to express a GPC3-targeting chimeric antigen receptor and IL-15.

Read More



10 views

Recent Posts

See All

Chemomab Completes Merger with Anchiano Therapeutics

Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol "CMMB" Combined company will focus on advancing Chemomab's CM-101 current

A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved